Harsch Mutya 4
4 · VYNE Therapeutics Inc. · Filed Jan 3, 2024
Insider Transaction Report
Form 4
Harsch Mutya
CHIEF LEGAL OFFICER AND GC
Transactions
- Tax Payment
Common Stock
2024-01-02$2.28/sh−161$367→ 149,435 total - Award
Stock Option (right to buy)
2024-01-01+62,500→ 62,500 totalExercise: $2.33Exp: 2033-12-31→ Common Stock (62,500 underlying) - Award
Common Stock
2024-01-01+62,500→ 149,596 total
Footnotes (4)
- [F1]Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
- [F2]The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
- [F3]Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.
- [F4]The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.